Evommune Inc. (EVMN)

Last Closing Price: 6.88 (2026-11-18)

Company Description

Evommune Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. Evommune Inc. is based in PALO ALTO, Calif.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $13.00M
Net Income (Most Recent Fiscal Year) $-68.87M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.99
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -946.68%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -43.53%
Return on Assets (Trailing 12 Months) -40.11%
Current Ratio (Most Recent Fiscal Quarter) 8.52
Quick Ratio (Most Recent Fiscal Quarter) 8.52
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $6.08
Earnings per Share (Most Recent Fiscal Quarter) $-0.85
Earnings per Share (Most Recent Fiscal Year) $-11.22
Diluted Earnings per Share (Trailing 12 Months) $-3.81
Stock
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 41.35M
Free Float 28.49M
Market Capitalization $284.49M
Average Volume (Last 20 Days) 1.02M
Beta (Past 60 Months) --
Percentage Held By Insiders (Latest Annual Proxy Report) 31.10%
Percentage Held By Institutions (Latest 13F Reports) --
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%